NEWS

Life Sciences Venture Fund aMoon Invests $5 Million in Cancer Drug Company

December 24, 2019

Israel-based life sciences, healthcare, and technology venture capital firm aMoon, together with an unnamed private investor, invested $5 million in cancer drug startup NanoGhosts, aMoon told Calcalist. This is NanoGhosts’s first investment.

Read More

Seer Announces $55 Million in Series D Equity Financing Bringing in New Investors aMoon Fund and T. Rowe Price Funds

December 19, 2019

Capital will enable continued advancement of novel Proteograph™ platform and commercialization of first-in-class proteomics products

Read More

Newly Merged Voice Analysis Startups Healthymize and Beyond Verbal Raise $9 Million

December 10, 2019

The new entity, Vocalis Health, will develop technology for the voice-based analysis and detection of health issues such as heart and respiratory conditions and depression

Read More

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

MDClone, Developer of First Healthcare Synthetic Data Engine, Raises $26 Million

August 22, 2019

aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.

Read More

Israel’s 10 ‘Hottest’ Startups In 2019, According to WIRED Magazine

August 21, 2019

Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”

Read More

Nobio gets FDA approval for anti-bacterial dental fillings

August 5, 2019

TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.

Read More

Can This Ancient Greek Medicine Cure Humanity?

July 26, 2019

There’s fresh interest in a fabled shrub on the Aegean island of Chios.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

Israeli health fund aMoon II raises $660 million

March 6, 2019

Israel-based healthcare fund aMoon II said on Wednesday it has received commitments of $660 million from investors. This is up from $600 million reported in January in an investor document obtained by Reuters.

Read More

A healthcare investment fund has become one of Israel’s largest with a $660 million close

March 6, 2019

One of Israel’s single largest venture capital funds is a new later stage vehicle focused on healthcare.

Read More

Ayala Pharmaceuticals to Present Preclinical Data at AACR for AL101, a Pan-Notch Inhibitor Being Evaluated for Adenoid Cystic Carcinoma

March 4, 2019

Results support the clinical development of AL101 as a targeted monotherapy for people with tumors bearing Notch activated mutations

Read More

Regenera Pharma Enrolls First Patient in US Phase 3 Study of RPh201 in NAION

August 2, 2018

Advances Phase 2 Study in Alzheimer’s Disease in Canada, RPh201 development in US supported by Fast Track Designation by US Food and Drug Administration

Read More

Israeli firm creates particles to kill germs on contact, fight bacterial disease

August 2, 2018

With product initially aimed for dental industry, Petah-Tikva based Nobio raises $3.6 million from aMoon Fund and Dr. Ole Jensen, a US surgeon and dentist

Read More

Zebra Medical Vision gets $30M Series C to create AI-based tools for radiologists

June 7, 2018

Zebra Medical Vision, an Israeli medical imaging startup that uses machine and deep learning to build tools for radiologists, has raised a $30 million Series C led by health technology fund aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation—JJDC Inc.

Read More

Medial EarlySign’s clinical validation trial shows promise for detecting colorectal cancer

April 17, 2018

A new clinical validation study, published in the Journal of Clinical Oncology CCI, found that Medial EarlySign’s artificial intelligence tool flagged about 8 percent of patients in a large trial group that were later diagnosed with cancer or precancerous lesions.

Read More

BiondVax, NIAID kick off phase 2 universal flu vaccine study in U.S.

April 11, 2018

Already gearing up for a late-stage universal flu vaccine test in European countries, BiondVax has attracted its first participant to a phase 2 study sponsored by the National Institute of Allergy and Infectious Diseases.

Read More

Mylan to Acquire the Global Marketing Rights to Glatiramer Acetate Product through Mapi Pharma

April 10, 2018

Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis.

Read More

Ayala notches up $17M in financing to push BMS drug into phase 2

April 10, 2018

Israeli biotech Ayala Pharmaceuticals, founded last year as a development vehicle for two of Bristol-Myers Squibb’s cancer candidates, has raised $17 million in a series A financing.

Read More